BUZZ-Law firm probes short-seller claims at ADMA Biologics; shares up

Reuters03-30

BUZZ-Law firm probes short-seller claims at <a href="https://laohu8.com/S/ADMA">ADMA Biologics</a>; shares up

** Shares of biotech firm ADMA Biologics ADMA.O rise 2% to $9.40 premarket

** Securities law firm Bleichmar Fonti & Auld says it is investigating the drugmaker for potential securities law violations

** Probe follows a March 24 report by short-seller Culper Research alleging the company used channel stuffing to inflate 2025 revenue

** Culper alleged ADMA encouraged distributors to stock excess Asceniv, an immune therapy for a rare immune system disorder, by offering rebates and extended payment terms

** Short-seller estimated ADMA’s revenue would have fallen 3% in 2025 without the alleged practice, versus the company’s reported 20% growth

** ADMA shares rose more than 6% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623316126?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623316126","market":"nz","top_or_hot":-1,"title":"BUZZ-Law firm probes short-seller claims at ADMA Biologics; shares up","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Law firm probes short-seller claims at <a href=\"https://laohu8.com/S/ADMA\">ADMA Biologics</a>; shares up</title></head><body><p>** Shares of biotech firm ADMA Biologics <span>ADMA.O</span> rise 2% to $9.40 premarket</p><p>** Securities law firm Bleichmar Fonti &amp; Auld says it is investigating the drugmaker for potential securities law violations</p><p>** Probe follows a <span>March 24 report</span> by short-seller Culper Research alleging the company used channel stuffing to inflate 2025 revenue</p><p>** Culper alleged ADMA encouraged distributors to stock excess Asceniv, an immune therapy for a rare immune system disorder, by offering rebates and extended payment terms</p><p>** Short-seller estimated ADMA’s revenue would have fallen 3% in 2025 without the alleged practice, versus the company’s reported 20% growth</p><p>** ADMA shares rose more than 6% in 2025</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Law firm probes short-seller claims at ADMA Biologics; shares up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Law firm probes short-seller claims at ADMA Biologics; shares up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-30 18:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Law firm probes short-seller claims at <a href=\"https://laohu8.com/S/ADMA\">ADMA Biologics</a>; shares up</title></head><body><p>** Shares of biotech firm ADMA Biologics <span>ADMA.O</span> rise 2% to $9.40 premarket</p><p>** Securities law firm Bleichmar Fonti &amp; Auld says it is investigating the drugmaker for potential securities law violations</p><p>** Probe follows a <span>March 24 report</span> by short-seller Culper Research alleging the company used channel stuffing to inflate 2025 revenue</p><p>** Culper alleged ADMA encouraged distributors to stock excess Asceniv, an immune therapy for a rare immune system disorder, by offering rebates and extended payment terms</p><p>** Short-seller estimated ADMA’s revenue would have fallen 3% in 2025 without the alleged practice, versus the company’s reported 20% growth</p><p>** ADMA shares rose more than 6% in 2025</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nL4N40I0SO:1","article_id":"2623316126","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623316126","pubTimestamp":1774866023,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Law firm probes short-seller claims at ADMA Biologics; shares up** Shares of biotech firm ADMA Biologics ADMA.O rise 2% to $9.40 premarket** Securities law firm Bleichmar Fonti & Auld says it is investigating the drugmaker for potential securities law violations** Probe follows a March 24 report by short-seller Culper Research alleging the company used channel stuffing to inflate 2025 revenue** Culper alleged ADMA encouraged distributors to stock excess Asceniv, an immune therapy for a rare immune system disorder, by offering rebates and extended payment terms** Short-seller estimated ADMA’s revenue would have fallen 3% in 2025 without the alleged practice, versus the company’s reported 20% growth** ADMA shares rose more than 6% in 2025","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ADMA":"ADMA Biologics Inc"},"translate_title":"BUZZ-律师事务所调查ADMA Biologics的卖空索赔；股票上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":0.9},"content_text":"BUZZ-Law firm probes short-seller claims at ADMA Biologics; shares up** Shares of biotech firm ADMA Biologics ADMA.O rise 2% to $9.40 premarket** Securities law firm Bleichmar Fonti & Auld says it is investigating the drugmaker for potential securities law violations** Probe follows a March 24 report by short-seller Culper Research alleging the company used channel stuffing to inflate 2025 revenue** Culper alleged ADMA encouraged distributors to stock excess Asceniv, an immune therapy for a rare immune system disorder, by offering rebates and extended payment terms** Short-seller estimated ADMA’s revenue would have fallen 3% in 2025 without the alleged practice, versus the company’s reported 20% growth** ADMA shares rose more than 6% in 2025(Reporting by Sahil Pandey in Bengaluru)((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623316126","isCrawlerRequest":true}